Albumin for Management of Hypervolemic Hyponatremia (AlbuCAT)
Status:
Not yet recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
resolution of hyponatremia, defined as an increase in serum sodium of more than 5 mEq/L with
a final value > 130 mEq/L, maintained for at least 48 consecutive hours during the 10-day
treatment period